Sanofi's Venglustat Earns FDA Breakthrough Therapy Designation for Gaucher Disease

Key Facts

1The US FDA granted Breakthrough Therapy designation to Sanofi's venglustat.

2The drug targets neurological manifestations of type 3 Gaucher disease (GD3), a rare genetic disorder.

3Venglustat is an investigational oral glucosylceramide synthase inhibitor (GCSi).

Sanofi has announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to its investigational drug, venglustat. The drug is specifically designed to treat the neurological manifestations of type 3 Gaucher disease (GD3), a rare and debilitating genetic disorder. Venglustat functions as an oral glucosylceramide synthase inhibitor (GCSi), aiming to address significant unmet medical needs in this patient population. This regulatory milestone is based on clinical evidence suggesting the drug may offer substantial improvement over existing therapies. The Breakthrough Therapy designation is expected to expedite the development and regulatory review process for Sanofi. This development strengthens Sanofi's position in the rare disease market and highlights its ongoing commitment to specialized biotechnology.

Create Free Account